Recently, anti-PD1 antibody (nivolumab) has been found to be ineffective against metastatic renal cell carcinoma, advanced squamous cell carcinoma, non-small-cell lung cancer, melanoma, or luminal-like breast cancer [48, 49]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.